Switching from Mounjaro Injection to Wegovy Tablets: A UK Patient's Guide

Reviewed by: Irfan Mahmud, Superintendent Pharmacist — GPhC Registration: 2080386 │ GPhC Pharmacy: 9012581 Last clinically reviewed: 24.06.2026

With the MHRA's approval of Wegovy tablets (oral semaglutide) for weight management on 11 June 2026, many people currently using Mounjaro are asking whether they can change their treatment format.

Can I move from a weekly injection to a daily tablet?

The short answer is yes, under clinical supervision, but this is one of the more involved switches in weight-loss medicine, because it means changing from one active medicine to another. Mounjaro and Wegovy are not the same drug, and moving between them is not a like-for-like swap. This guide explains, honestly, why someone might switch, what genuinely changes, how the transition is managed safely, and the one practical reality you need to know before you plan anything: the tablet is approved but not yet commercially available in the UK.

⚠ Before you read on: Wegovy tablets are not yet on sale in the UK

Wegovy tablets received MHRA approval on 11 June 2026 but have not yet launched commercially. Commercial availability is expected on 7 July 2026, and they are not yet available on the NHS. You cannot obtain them today, and no legitimate UK pharmacy can dispense them until they are in stock. What you can do now is understand the switch, plan it with your prescriber, and be ready when the tablet becomes available. Avoid any website claiming to supply "oral Wegovy" before the official UK launch.

Can you switch from Mounjaro to Wegovy tablets?

Yes, switching from Mounjaro (tirzepatide) injections to Wegovy (semaglutide) tablets is a recognised and medically valid transition, but it must be done under the supervision of a prescriber, and it rests on two facts that shape everything that follows.

First, these are different medicines. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Wegovy tablets contain semaglutide, a GLP-1 receptor agonist. Because they are different molecules, there is no direct, dose-for-dose conversion between them. You cannot simply match your Mounjaro dose to an equivalent tablet dose. Your prescriber maps an appropriate starting point based on your current dose, how long you have been treated and how well you tolerate the medication.

Second, the tablet has not yet launched. Approval and availability are separate steps. This means a Mounjaro-to-tablet switch is, for now, something to plan rather than to execute. The clinical principles below apply equally to switching to the Wegovy injection (available now) and to the tablet (when it arrives 7 July 2026), with one major addition for the tablet, a strict daily fasting routine, covered later.

If you simply want to move off injections immediately and the tablet's launch timing does not suit you, switching to the Wegovy injection is possible today, the tablet can be considered once it is in stock.

Sources: MHRA First GLP-1 tablet for weight loss approved in the UK, 11 June 2026; UK clinical switching guidance, 2026.

Why might someone switch from Mounjaro to Wegovy tablets?

There is no single right reason, and the decision is always individual. The most common, legitimate reasons UK patients consider this switch include:

● Avoiding needles. This is the headline reason the tablet exists. For people who tolerate Mounjaro's weekly injection but dislike it, or who have developed injection fatigue over months of treatment, a daily tablet removes the needle entirely.

● Cost. Following Eli Lilly's price changes in late 2025, Wegovy is now generally more affordable than Mounjaro for many private patients. Exact tablet pricing in the UK has not yet been confirmed, but the broader trend has made semaglutide the more economical option for a significant number of people.

● Supply and availability. Patients who have experienced stock interruptions with one medicine sometimes prefer the reassurance of an alternative supply chain.

● Side-effect tolerability. Some people find the side-effect profile of semaglutide suits them better than tirzepatide, although the two are broadly comparable and individual experience varies.

● The contraceptive-pill consideration. Mounjaro can reduce the absorption of oral contraceptive pills, particularly during dose escalation, which is why barrier contraception is advised. Semaglutide has no clinically relevant effect on the effectiveness of oral contraceptives. For women who rely on the pill, this is a genuine practical advantage of switching to a semaglutide medicine.

● Treatment phase. Some patients who have reached or are approaching their goal weight feel that a once-daily tablet is a more sustainable way to maintain their results long-term.

Reasons you might not switch

Honesty matters here, because the most important counterpoint is rarely stated plainly by other providers:

If Mounjaro is working well for you, particularly at a higher dose, switching to Wegovy tablets may mean accepting somewhat less weight loss.

Tirzepatide, especially at its higher maintenance doses, tends to produce greater average weight loss than oral semaglutide. Real-world observational data has shown tirzepatide users losing around 22% of their starting weight at 12 months, compared with around 17% for semaglutide users, though this was not a randomised head-to-head comparison. If you are losing weight well on Mounjaro and your only frustration is the needle, that trade-off is worth discussing carefully with your prescriber before you decide.

The right answer depends on what matters most to you: maximum weight loss, or the convenience and comfort of a needle-free daily tablet.

Sources: Real-world programme data (tirzepatide vs semaglutide, 12-month outcomes), 2025/26; MHRA Summary of Product Characteristics — Mounjaro; semaglutide.

Mounjaro vs Wegovy tablets: what actually changes

Three things change when you move from Mounjaro injections to Wegovy tablets UK Guide, the medicine, the format, and what you can realistically expect.

The headline takeaway: you gain convenience, room-temperature storage and freedom from needles, and you remove the contraceptive-absorption concern, but you move to a medicine whose peak efficacy is closer to the standard Wegovy injection than to higher-dose Mounjaro, and you take on a demanding daily fasting routine.

How the switch works: the gap and your starting dose

Because Mounjaro and Wegovy are different medicines, the switch follows a clinical process rather than a simple substitution. Two elements matter most: the gap between medicines, and your starting tablet dose.

The gap between your last Mounjaro injection and your first Wegovy dose

You must never take Mounjaro and Wegovy at the same time. A short gap is left between your final Mounjaro injection and your first dose of the new medicine, both to let the tirzepatide clear and to reduce the chance of overlapping side effects.

In current UK practice, that gap is usually:

● Around 7 days after your last Mounjaro injection if you had no, or only mild, side effects. This conveniently aligns with Mounjaro's weekly dosing schedule, you simply start the new medicine on the day your next injection would have been due.

● Around 14 days if you experienced severe side effects on Mounjaro, giving your body longer to settle before starting again.

Tirzepatide has a half-life of roughly 5 days, so it remains active in your system for several days after your last injection. For this reason, a long "washout" is generally not necessary, and many people notice little change in appetite during the gap. Your prescriber will confirm the exact timing for you.

Your starting tablet dose

Because there is no dose-for-dose equivalence between tirzepatide and semaglutide, your prescriber maps your starting tablet dose individually. In practice, most people begin at or near the lowest tablet dose (1.5 mg) and titrate upwards through the standard schedule, with a minimum of one month at each step.

Crucially, you are not starting from scratch. Having already been on a GLP-1-based medicine, your digestive system is partly adapted to this class, so re-titration is often more comfortable than it was the first time around. That said, the safest default, especially if you had significant side effects on Mounjaro, is a cautious, lower start.

⚠ Never take Mounjaro and Wegovy together

Combining tirzepatide and semaglutide is not a way to enhance results, it increases the risk of side effects without an established benefit, and it is not clinically appropriate. Always complete the prescribed gap before starting your new medicine, and only ever take one GLP-1 medicine at a time.

Sources: UK clinical switching guidance (tirzepatide to semaglutide), 2026; MHRA Summary of Product Characteristics — Mounjaro; Wegovy.

What to expect during the transition

Switching medicines is rarely dramatic, but there are a few changes worth anticipating so they do not catch you off guard.

Appetite may feel different at first. Semaglutide's effect tends to build gradually as you titrate, so in the early weeks your appetite control may feel less pronounced than it did at your established Mounjaro dose. This usually settles as you move up the dose ladder. Some people notice a temporary increase in appetite during the gap between medicines, this is expected and short-lived.

Side effects during re-titration are usually milder. Because you are already adapted to GLP-1-class medicines, the gastrointestinal effects of starting again, nausea, occasional digestive upset, are typically less intense than for someone entirely new to treatment. They still tend to be most noticeable in the days after each dose increase.

Your weight may plateau briefly. A short pause in progress around the switch is common and not a cause for alarm. Consistent results usually resume as you reach your effective maintenance dose.

Your daily routine will change. This is the largest practical adjustment, and it deserves its own section.

The fasting protocol: the biggest day-to-day change

This is where switching to the tablet differs most from anything you experienced on Mounjaro. The Mounjaro injection could be taken at any time of day, with or without food. The Wegovy tablet cannot.

Oral semaglutide is poorly absorbed unless taken under specific conditions, so the rules are not optional, they directly determine whether the medicine reaches your bloodstream:

1. Take the tablet first thing in the morning, on an empty stomach, after fasting overnight (at least 8 hours without food).

2. Swallow it whole with a small sip of plain water only, do not crush, split or chew it.

3. After taking it, wait at least 30 minutes before eating, drinking anything else, or taking any other oral medication.

For someone used to the flexibility of a weekly injection, this is a meaningful shift. The most reliable approach is to take the tablet the moment you wake, then use the 30-minute window for your morning routine before breakfast. If a consistent fasted morning is genuinely difficult for your circumstances, for example, if you do shift work, raise this during your consultation, as the Wegovy injection or, in time, a different oral GLP-1 with less strict timing may suit you better.

Sources: MHRA administration guidance for semaglutide tablets, 11 June 2026; MHRA Summary of Product Characteristics — semaglutide tablet.

Side effects and safety

The side-effect profile of Wegovy tablets is the well-characterised semaglutide profile. The most common effects are gastrointestinal and are usually most noticeable when starting or stepping up a dose:

● nausea

● vomiting

● diarrhoea

● constipation

● abdominal pain or discomfort

These typically ease as your body adapts, and slow titration is designed to keep them manageable. Staying hydrated, eating smaller meals and avoiding very rich or fatty foods can help during dose increases.

Less common but more serious risks associated with the GLP-1 class include pancreatitis, gallbladder problems and dehydration-related effects on the kidneys. Seek prompt medical advice for severe or persistent abdominal pain, signs of dehydration, or any reaction that concerns you.

One welcome change for some patients: unlike Mounjaro, semaglutide does not have a clinically relevant effect on the absorption of oral contraceptive pills, so the additional barrier-contraception precaution advised with Mounjaro is not needed once you have switched. As always, tell your prescriber about every medicine you take so they can advise on timing and interactions.

Report side effects via the MHRA Yellow Card scheme: yellowcard.mhra.gov.uk, or search "MHRA Yellow Card" in the App Store or Google Play.

Sources: MHRA Summary of Product Characteristics — semaglutide; Mounjaro; MHRA Yellow Card scheme.

Cost and availability

As of 7 July 2026, Wegovy tablets are MHRA-approved but not yet commercially available, and not available on the NHS. When they launch, initial access is expected to be via private prescription, dispensed by a GPhC-registered pharmacy following a clinical assessment.

UK pricing for the tablet has not yet been confirmed; we will publish indicative costs once they are available. Tablet pricing in £ to be confirmed at launch on our online store. More broadly, semaglutide has become the more economical option for many private patients relative to Mounjaro, which is one of the reasons interest in this switch is high.

If you would like to plan a switch in advance of the tablet's launch, the practical step now is a consultation to confirm whether the switch is clinically appropriate for you, so that you are ready to proceed as soon as the medicine is in stock.

Frequently asked questions

Can I switch straight from Mounjaro to Wegovy tablets?

You can switch under clinical supervision, but not on a one-to-one basis, they are different medicines, so your prescriber maps a suitable starting tablet dose. Note that the tablet is not yet commercially available in the UK, so for now this is a switch to plan rather than to make immediately.

Do I need a washout period?

A short gap, not a long washout. In current UK practice this is usually around 7 days after your last Mounjaro injection (often aligning with your next due dose), or around 14 days if you had severe side effects. Your prescriber will confirm the timing.

Will I lose less weight on Wegovy tablets than on Mounjaro?

Possibly, particularly if you were on a higher Mounjaro dose. Tirzepatide tends to produce greater average weight loss than oral semaglutide, which is broadly comparable to the standard 2.4 mg Wegovy injection. If Mounjaro is working well for you, weigh that trade-off carefully against the convenience of a tablet. Individual results vary.

Can I take Mounjaro and Wegovy tablets at the same time?

No. The two should never be combined. Always complete the prescribed gap and take only one GLP-1 medicine at a time.

Do Wegovy tablets affect the contraceptive pill the way Mounjaro can?

No. Semaglutide has no clinically relevant effect on the effectiveness of oral contraceptives, so the extra barrier-contraception precaution advised with Mounjaro is not required.

When will Wegovy tablets be available in the UK?

They were approved on 11 June 2026 but have not yet launched commercially, and it is expected to launch on 7 July 2026. A confirmed launch date has not been announced. Check with a registered UK pharmacy for confirmed prescribing availability.

Making the Decision: Is it Right for You?

Switching from Mounjaro injections to Wegovy tablets is a legitimate, recognised transition that will appeal most to people who want to leave needles behind, value convenience and room-temperature storage, or prefer a more economical long-term option. It removes the contraceptive-absorption concern that comes with Mounjaro, and for many patients it offers a sustainable, comfortable way to continue treatment.

It is not, however, a like-for-like upgrade. You move to a different medicine with peak efficacy closer to the standard Wegovy injection than to higher-dose Mounjaro, and you take on a strict daily fasting routine in place of a flexible weekly injection. And, for now, you cannot actually make the switch until the tablet launches in the UK.

The sensible path is to plan, not rush: a clinical consultation can establish whether the switch suits your goals and medical history, so that if and when you decide to proceed, it is done safely and at the right starting dose.

For the full picture on the tablet itself, see our guide to Wegovy Tablets (Oral Semaglutide). If you are switching from the Wegovy injection rather than Mounjaro, see Switching from Wegovy Injection to Wegovy Tablets, a simpler, same-medicine transition. And for a complete comparison of the two injections, see Mounjaro vs Wegovy.

This article has been reviewed and approved by Irfan Mahmud, Superintendent Pharmacist (GPhC Registration: 2080386). Dispensed by our GPhC-registered pharmacy (Registration: 9012581), regulated by the General Pharmaceutical Council.

This content is for informational purposes only and does not constitute medical advice. All treatments are prescription-only medicines (POM). Consult a qualified healthcare professional before starting, stopping or changing any medication. Report suspected side effects via the MHRA Yellow Card scheme: yellowcard.mhra.gov.uk.

Last clinically reviewed: 24.06.2026.